Global Metabolism Drugs Market to Grow at 5.7% CAGR, Reaching USD 22.91 Billion by 2032

Global Metabolism Drugs market is experiencing steady expansion, driven by increasing prevalence of metabolic disorders, advancements in targeted therapies, and growing healthcare expenditure across both developed and emerging regions. According to a new report from Intel Market Research, the market—valued at USD 15,640 million in 2024—is projected to reach USD 22,910 million by 2032, advancing at a CAGR of 5.7% during 2025–2032. The report provides a comprehensive overview of key market dynamics including production and consumption patterns, segmentation by drug type and application, regional insights, market drivers, challenges, and competitive landscape.